Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $93.8333.

A number of brokerages have weighed in on PCVX. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price target on shares of Vaxcyte in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Guggenheim reiterated a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a report on Monday, February 2nd. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, Needham & Company LLC upped their price objective on shares of Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th.

Insiders Place Their Bets

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the sale, the insider directly owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Elvia Cowan sold 11,623 shares of Vaxcyte stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president owned 14,534 shares in the company, valued at $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PCVX. EverSource Wealth Advisors LLC grew its stake in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the last quarter. Allworth Financial LP grew its position in Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Vaxcyte during the 3rd quarter worth about $45,000. CIBC Private Wealth Group LLC increased its holdings in shares of Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock worth $49,000 after purchasing an additional 1,350 shares during the period. Finally, CWM LLC raised its position in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after buying an additional 1,115 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Trading Down 1.0%

PCVX stock opened at $55.57 on Tuesday. The firm has a market cap of $7.27 billion, a PE ratio of -11.48 and a beta of 1.33. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $87.42. The company has a fifty day simple moving average of $48.24 and a 200 day simple moving average of $41.68.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.